These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31170814)

  • 21. Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis.
    Stone A; Zukerman T; Flaishon L; Yakar RB; Rowe JM
    Leuk Res; 2019 Jul; 82():36-42. PubMed ID: 31152922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Demolis P; Béhanzin E; Moreau A; Hudson I; Flores B; Stemplewski H; Salmonson T; Gisselbrecht C; Bowen D; Pignatti F
    Oncologist; 2016 Jun; 21(6):692-700. PubMed ID: 27091416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
    Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
    Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
    Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
    Wu W; Lin Y; Xiang L; Dong W; Hua X; Ling Y; Li H; Yan F; Xie X; Gu W
    Ann Hematol; 2016 Jun; 95(7):1051-7. PubMed ID: 27116384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Thomas XG; Arthur C; Delaunay J; Jones M; Berrak E; Kantarjian HM
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):68-72. PubMed ID: 24220616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.
    Gupta N; Miller A; Gandhi S; Ford LA; Vigil CE; Griffiths EA; Thompson JE; Wetzler M; Wang ES
    Am J Hematol; 2015 Jul; 90(7):639-46. PubMed ID: 25808347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Daver N; Kantarjian H; Garcia-Manero G; Jabbour E; Borthakur G; Brandt M; Pierce S; Vaughan K; Ning J; Nogueras González GM; Patel K; Jorgensen J; Pemmaraju N; Kadia T; Konopleva M; Andreeff M; DiNardo C; Cortes J; Ward R; Craig A; Ravandi F
    Haematologica; 2017 Oct; 102(10):1709-1717. PubMed ID: 28729302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of 10-day decitabine in acute myeloid leukemia.
    Bouligny IM; Mehta V; Isom S; Ellis LR; Bhave RR; Howard DS; Lyerly S; Manuel M; Dralle S; Powell BL; Pardee TS
    Leuk Res; 2021 Apr; 103():106524. PubMed ID: 33640708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.
    Bocchia M; Candoni A; Borlenghi E; Defina M; Filì C; Cattaneo C; Sammartano V; Fanin R; Sciumè M; Sicuranza A; Imbergamo S; Riva M; Fracchiolla N; Latagliata R; Caizzi E; Mazziotta F; Alunni G; Di Bona E; Crugnola M; Rossi M; Consoli U; Fontanelli G; Greco G; Nadali G; Rotondo F; Todisco E; Bigazzi C; Capochiani E; Molteni A; Bernardi M; Fumagalli M; Rondoni M; Scappini B; Ermacora A; Simonetti F; Gottardi M; Lambertenghi Deliliers D; Michieli M; Basilico C; Galeone C; Pelucchi C; Rossi G
    Hematol Oncol; 2019 Oct; 37(4):447-455. PubMed ID: 31385337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
    Li WY; Wang Y; Chen SN; Qiu HY; Fu ZZ; Wu DP; Sun AN
    Leuk Lymphoma; 2018 Jul; 59(7):1652-1658. PubMed ID: 29043875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Zhu Y; Zhao H; Zhang X; Wu Y; Xie Y; Li Y; Lian Y; Huang J; Li J; Chen Y; Qian S
    Biol Blood Marrow Transplant; 2017 May; 23(5):830-835. PubMed ID: 28189902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
    Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
    Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
    J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decitabine for acute myeloid leukemia.
    Marks PW
    Expert Rev Anticancer Ther; 2012 Mar; 12(3):299-305. PubMed ID: 22369322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
    Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
    Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
    Santini V; Allione B; Zini G; Gioia D; Lunghi M; Poloni A; Cilloni D; Sanna A; Masiera E; Ceccarelli M; Abdel-Wahab O; Terenzi A; Angelucci E; Finelli C; Onida F; Pelizzari A; Ferrero D; Saglio G; Figueroa M; Levis A
    Leukemia; 2018 Feb; 32(2):413-418. PubMed ID: 28607470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.